Alcohol addiction is a chronic, relapsing and progressive brain disease with serious consequences for health. Compulsive use of alcohol is associated with the capacity to change brain structures involved with the reward pathway, such as ventral striatum. Recent evidence suggests a role of chromatin remodeling in the pathophysiology of alcohol dependence and addictive-like behaviors. In addition, neuroadaptive changes mediated by the brain-derived neurotrophic factor (BDNF) seems to be an interesting pharmacological target for alcoholism treatment. In the present study, we evaluated the effects of the deacetylase inhibitor valproic acid (VPA) (300 mg/kg) on the conditioned rewarding effects of ethanol using conditioned place preference (CPP) (15% v/ v; 2 g/kg). Ethanol rewarding effect was investigated using a biased protocol of CPP. BDNF levels were measured in the ventral striatum. Ethanol administration induced CPP. VPA pretreatment did not reduce ethanol-CPP acquisition. VPA pretreatment increased BDNF levels when compared to ethanol induced-CPP. VPA pretreatment increased BDNF levels even in saline conditioned mice. Taken together, our results indicate a modulatory effect of VPA on the BDNF levels in the ventral striatum. Overall, this study brings initial insights into the involvement of neurotrophic mechanisms in the ventral striatum in ethanol-induced addictive-like behavior.
The interplay between ventro striatal BDNF levels and the effects of valproic acid on the acquisition of ethanol-induced conditioned place preference in mice 
Introduction
Alcohol addiction is a chronic, relapsing and progressive brain disorder with serious consequences for health [1] . Compulsive ethanolseeking behavior has been associated with the activation of the reward system. Positive reinforcement is described as a situation in which a presumably rewarding stimulus or experience (e.g., alcohol-induced euphoria) increase the probability of the individual to exhibit a certain response (e.g., alcohol-seeking behavior) [1] . Overall, the reinforcement effects of drugs are related to the activation of the mesocorticolimbic dopaminergic system [2] .
The conditioned place preference (CPP) paradigm is widely used as a measurement of the rewarding effects of drugs. Here, we used the CPP paradigm to determine whether valproic acid (VPA) has the ability to alter the conditioned rewarding effects of ethanol. This behavioral approach investigates the reinforcing properties of drugs and the development of maladaptative behaviors, such as conditioned response to drug-associate stimuli [3] [4] [5] .
The reward circuit in the brain comprises dopaminergic neurons in the ventral tegmental area (VTA) that project to the nucleus accumbens (NAc), which is part of the ventral striatum [6] . This VTA-NAc circuit is crucial for the recognition of rewards in the environment and for initiating their consumption [7] . Dopaminergic neurons from the VTA also innervate several regions of the prefrontal cortex (PFC), central amygdala, basolateral amygdala and hippocampus [6] .
Genetic and epigenetic mechanisms play a pivotal role in the development of alcohol dependence [8] . Based on epigenetic mechanisms, chromatin remodeling induces modifications in BDNF gene expression during neurogenesis [9, 10] . Thus, BDNF seems to contribute to the neuroadaptative disruption induced by drugs of abuse, suggesting a participation of the BDNF pathway in drug dependence [11] . Furthermore, alcohol addicted patients presented with lower levels of plasma BDNF in relation to non-addicted ones [12] . In an animal model based on voluntary alcohol intake, alcohol-preferring rats have shown lower expression of BDNF transcripts in the NAc compared to alcohol nonpreferring animals [13] . Accordingly, these results suggest that the downregulation of BDNF could be related to the susceptibility to alcohol abuse. In order to reduce the incidence of alcohol dependence as well as the extension of the toxic effects induced by the compulsive consumption of this drug -such as neurotoxicity and hepatotoxicityseveral groups are investigating new pharmacological strategies along with non-pharmacological approaches to further our understanding of the neurobiology of alcohol addiction and its treatment [14] [15] [16] [17] [18] . To date, the anti-craving medications acamprosate and naltrexone are available for ethanol dependence treatment, however this therapy presents some disadvantage such as limited efficacy and low patient compliance [19] .
Thus, considering the limitations of the current anti-craving medications, VPA is an emerging new pharmacotherapy for the treatment of ethanol addiction. For such purpose, VPA effects and mechanisms in the reward system need to be investigated. Researchers have found evidence which indicates that VPA reduces drug-seeking behavior in animals and drug relapse in humans [20] [21] [22] . Therefore, in the present study we aimed to investigate the VPA effects on conditioned rewarding properties of ethanol and on ventro striatal BDNF levels.
Materials and methods

Animals
Male Swiss mice weighing 20-30 g, obtained from the animal house of the Department of Physiology and Pharmacology of the Universidade Federal do Ceara were used. Mice were housed eight per cage in a 12-h light/dark cycle (lights on at 7 a.m.) with food and water ad libitum, except during conditioning and test sessions. All conditioning and test sessions were conducted during the light phase (between 8 a.m. and 4 p.m.). The room temperature was maintained at 23 ± 2°C and relative humidity at 60 ± 5%. All experimental procedures were performed in accordance with the National Institutes of Health Guide and Use of Laboratory Animals and approved by the local ethical committee of animal use (protocol number 63/16).
Drugs
For ethanol-induced CPP, ethanol solution (15% v/v) was prepared from absolute ethyl alcohol (Merck ® , Darmstadt, Germany) and diluted in 0.9% sodium chloride (saline). Saline or ethanol was given by intraperitoneal (i.p.) injection in the conditioning sessions. Valproic acid (VPA -300 mg/kg) was dissolved in saline and then administered by oral route. The oral administration of VPA was based on the clinical use of this drug [23] . The dose of VPA was chosen based on a previous study [20] .
Experimental design
Mice were divided into groups conditioned with saline or ethanol. Pretreatment groups received saline or VPA 30 min prior to conditioning with saline or ethanol. It is important to mention that in most conditioning protocols [24] , the drug pretreatment timing varied from 10 min up to 2 h [25, 26] . After the CPP procedure, mice were euthanized by decapitation and the ventral striatum was dissected following the anatomical coordinates [27] using brain matrices for mice (EFF 511, Insight ® ). The samples were rapidly frozen and stored at −80°C for the measurement of BDNF levels.
Ethanol-induced conditioned place preference
Conditioned place preference was performed using two identical boxes, each one consisting in three rectangular chambers separated by guillotine doors. Each box has two conditioning compartments (200 mm long × 140 mm wide × 150 mm high) separated from each other by a small center chamber (40 mm long × 140 wide × 150 mm high). The two chambers were distinguishable by visual cues on the walls (black versus white horizontal stripes and vertical stripes) and floor texture (grid versus rubber). The central compartment has black walls and two guillotine doors. The trajectory of the animals was monitored by a video camera and the time spent in each compartment was measured manually.
A biased apparatus was used in the CPP paradigm. Mice showed a baseline preference for one or other compartment, in this way, the drug-paired chamber choice was counterbalanced. The CPP procedure was based on a previous protocols [20] . The CPP procedure consisted of three phases: preconditioning, conditioning and test.
Preconditioning
On the first day of experiment, all subjects were injected with saline (10 ml/kg body weight i.p) and immediately placed in the center of the chamber with the guillotine doors raised, this allowed the mice to explore both conditioning compartments for 30 min. The time spent in each compartment was manually scored.
Conditioning
Over the next four days, mice received alternating intraperitoneal injections (two injections per day) of vehicle or ethanol (2 g/kg). Immediately following the administration of the conditioning drug or vehicle, mice were placed into one of the two conditioning compartments for 30 min. Vehicle-and ethanol-paired compartments were counterbalanced within each group. The pretreatment, vehicle (saline) or valproic acid, was administered 30 min prior to ethanol or saline injections and mice were immediately placed in their respective compartment.
Post conditioning test
The post conditioning test was conducted on day 6 as mentioned in the preconditioning protocol.
Determination of BDNF levels in the ventral striatum
Brain derived neurotrophic factor was determined in the ventral striatum by enzyme immunoassay according to the manufacturer's recommendations (ELISA; Millpore, USA). Results are expressed as pg/g of wet tissue.
Statistical analysis
In CPP procedures, the conditioning behavior was determined by subtracting the time (in seconds) spent in the saline-paired compartment from the time spent in ethanol-paired compartment, as described elsewhere [25] . Statistical analyses were performed with GraphPad Prism 6.0 for Windows, GraphPad Software (San Diego, CA, USA). Behavioral and BDNF data were analyzed by regular two-way ANOVA with "Ethanol conditioning" (vehicle and ethanol) and "Drug pretreatment" (Vehicle and VPA) as factors. In the case of a significant effect of each factor or their interaction, Tukey's post-hoc test was used. All results are expressed as means ± SEM (standard errors of the mean). Before ANOVA, D'Agostino-Pearson omnibus test was conducted to verify the normal distribution of the data. For all analyses, the significance level was set at P ≤ 0.05.
Results
To further evaluate whether VPA alters the conditioned rewarding effects of ethanol, we tested mice for ethanol-induced CPP. As shown in Fig. 1 , a two-way ANOVA revealed no significant interaction between "Ethanol conditioning" x "Drug pretreatment" [F(1, 28) = 2.204, P = 0.1488], however, a significant main effect of "Ethanol conditioning" [F(1,28) = 20.42, P = 0.0001) and "Drug pretreatment" [F (1, 28) = 56.63, P < 0.0001)] was observed. Post hoc test showed that ethanol conditioning increased the time in the drug-paired compartment when compared to vehicle conditioning (P < 0.0001). On the other hand, VPA pretreatment reduced the time in the drug-paired compartment in relation to vehicle pretreatment prior to ethanol conditioning (P < 0.01). Fig. 2 shows the effects of ethanol-induced CPP and VPA pretreatment on ventro-striatal BDNF levels after conditioning. The two-way ANOVA revealed a significant interaction between "Ethanol conditioning" x "Drug pretreatment" [F(1,28) = 10.24, P = 0.0034]. A significant main effect of "Drug pretreatment" was also observed [F(1, 28) = 167.3, P < 0.0001). Post hoc test showed that VPA pretreatment prior to ethanol conditioning increased BDNF levels in the ventral striatum when compared to vehicle pretreatment prior to ethanol conditioning (P < 0.0001). This elevation of BDNF levels observed in VPA-treated mice was also significant when compared to vehicle pretreatment prior to vehicle conditioning (P < 0.0001).
Discussion
In the present study, we observed that VPA did not affect ethanolinduced CPP acquisition. On the other hand, previous experiments showed that VPA 300 mg/kg decreased ethanol consumption in the two-bottle choice test and blocked ethanol-induced CPP acquisition (ethanol 0.5 g/kg, i.p.) using a different CPP procedure [20] . GABAergic neurotransmission seems to play an important role in ethanol rewarding effect. Thus, these authors concluded that VPA behavioral effects could be related to increased GABAergic transmission due to GABA aminotransaminase inhibition [28] . In line with this evidence, a potent inhibitor of GABA transaminase, CPP-115, blocked cocaine-induced CPP. Moreover, CPP-115 inhibits cocaine-induced increase of extracellular dopamine levels in the nucleus accumbens [29] .
The neuroanatomy and functioning of the reward system includes a complex network comprising the nucleus accumbens, ventral tegmental area, prefrontal area and others. Therefore, we aimed to analyze the neurotrophin, BDNF, involved with synaptic plasticity and neurons survival in the ventral striatum, where NAc is located [30] .
In this study, we observed that VPA pretreatment prior to ethanol conditioning increased BDNF levels in the ventral striatum when compared to vehicle pretreatment prior vehicle conditioning. Previous studies suggested an involvement of BNDF in the rewarding effects of drugs of abuse. In line with this evidence, Raivio et al. [31] showed that the acute administration of ethanol decreases hippocampal BDNF mRNA transcripts in the frontal cortex, amygdala and NAc. On the contrary, higher doses of ethanol increased the expression of BDNF transcripts in the VTA. These results indicate that the effect of acute ethanol administration on the reward system is brain-area dependent.
BDNF signaling has been studied as a modulatory pathway to alcohol 5 dependence. Mcgough [32] demonstrated that this neurotrophin attenuates some 6 behavioral effects of ethanol such as selfadministration. Low BDNF levels lead to a 7 greater responsiveness to ethanol-related behaviors. On the other hand, higher BDNF 8 levels attenuate those behaviors. Previous data support the idea that the activation of the 9 BDNF pathway in the dorsal striatum decreases alcohol-induced drinking behavior and 10 rewarding effects [33] . In this regard, hereupon, a pharmacological agent capable of 11 enhancing BDNF levels could down regulate the ethanol behavioral effects.
Previous data have shown that the acute and repeated administration of VPA increases BDNF expression in prefrontal cortex and hippocampus [34] . Modulation of hippocampal plasticity is associated with early memory formation on context-drug learning [2] .
VPA induces ERK1/2 phosphorylation in rodents brain, which, in turn, activates transcription and increases c-Fos expression [35] . The activation of the ERK pathway is known to increase BDNF levels in the dentate gyrus of hippocampal formation and PFC [36] . Furthermore, consistent evidence suggests that the negative modulatory effect of BDNF on ethanol intake is related to the activation of MAPK-ERK pathway in the striatum [37] .
To date, previous studies searching for the role of BDNF in the behavioral alterations induced by drugs of abuse revealed that this neurotrophin is associated with a facilitation or inhibition of drug-induced self-administration or CPP depending on the drug studied, addiction phase, specific brain region or animal model used.
Therefore, our results suggest that ethanol produced conditioned place preference using this procedure. However, conditioning with ethanol did not affect BDNF levels in ventral striatum, demonstrating that in this CPP procedure seems like there is no relationship between reinforcing effects of ethanol and ventro-striatal BDNF levels. On the other hand, the pretreatment with valproic acid did not decrease ethanol-induced CPP acquisition, despite of the increment of BDNF levels observed in the ventral striatum. Thus, it is necessary to encourage the search for a better understanding of conditioned behavior and BNDF signaling. /kg, i.p.) . Data of conditioned place preference test were represented as mean ± SEM of seconds in the drug-paired box (n = 8 animals/group). Accordingly, to two-way ANOVA, there was no interaction between factors. EtOH = ethanol; VEH = saline; VPA = valproic acid. Fig. 2 . Levels of brain-derived neurotrophic factor (BDNF) in ventro-striatum of mice conditioned with EtOH or VEH and pretreated with VEH or VPA (300 mg/kg). Bars represent mean ± SEM of the levels of BDNF (n = 8 animals/group). ****P < 0.0001 according to two-way followed by Tukey's post hoc test. EtOH = ethanol; VEH = saline; VPA = valproic acid.
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